Hemostats – Health Economics

  1. Perioperative Blood Loss Predictors, Evaluation and Management
  2. Hemostats – Health Economics

2011
Ye, X., et al. "Readmission rates and costs associated with fibrin sealant use among patients undergoing orthopedic surgery." Value in Health 14.3 (2011): A80.

2015
Scardino, M., F. Martorelli, and G. Grappiolo. "Evicel and Bloodless Protocol In Orthopaedics Surgery Clinical Evidence And Cost-Analysis: Italian Experience Humanitas Research Hospital." Value in Health 18.7 (2015): A664.

David, Guy, et al. "Similar patient outcomes yet different hospital costs between flowable hemostatic agents." Journal of medical economics 18.9 (2015): 735-745.

Faivre, P., S. Laplante, and H. Kreuwel. "Multi European Country Cost Consequence Comparison Of Floseal Matrix And Surgiflo Thrombin In Major And Severe Spine Surgeries." Value in Health 18.7 (2015): A370.

2016
Makhija, D., et al. "COST CONSEQUENCE ANALYSIS OF TWO DIFFERENT ACTIVE FLOWABLE HEMOSTATIC MATRICES IN SPINE SURGERY PATIENTS (US HOSPITAL PROVIDER PERSPECTIVE)." Value in Health 19.3 (2016): A233.